Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors

Journal of the American Medical Directors Association

Volumn 17, Issue 10, 2016, Pages 896-901

  Rizzo, Maria Rosaria ^a   Barbieri, Michelangela ^a   Fava, Ilaria ^a   Desiderio, Manuela ^a   Coppola, Carla ^a   Marfella, Raffaele ^a   Paolisso, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

aging; DPP4 I; Sarcopenia; type 2 diabetes mellitus

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

4 M GAIT SPEED TEST; AGED; ARTICLE; BIOELECTRICAL IMPEDANCE ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DYNAMOMETER; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FAT FREE MASS; FEMALE; GAIT SPEED; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; MUSCLE STRENGTH; MUSCULOSKELETAL DISEASE ASSESSMENT; MUSCULOSKELETAL SYSTEM PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETERS; SARCOPENIA; SKELETAL MUSCLE; SKELETAL MUSCLE MASS; TEST MEAL; AGING; LABORATORY TECHNIQUE; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; CLINICAL LABORATORY TECHNIQUES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MUSCLE STRENGTH; SARCOPENIA;

EID: 84976548102     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2016.04.016     Document Type: Article

References (40)

1. 1 Lexell, J., Human aging, muscle mass, and fiber type composition. J Gerontol A BiolSci Med Sci 50 (1995), 11–16.
2. 2 Frontera, W.R., Hughes, V.A., Fielding, R.A., et al. Aging of skeletal muscle: A 12-yr longitudinal study. J Appl Physiol 88 (2000), 1321–1326.
3. 3 Brady, A.O., Straight, C.R., Evans, E.M., Body composition, muscle capacity, and physical function in older adults: An integrated conceptual model. J Aging Phys Act 22 (2014), 441–452.
4. 4 Ali, S., Garcia, J.M., Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options—a mini-review. Gerontology 60 (2014), 294–305.
5. 5 Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39 (2010), 412–423.
6. 6 Fielding, R.A., Vellas, B., Evans, W.J., et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 12 (2011), 249–256.
7. 7 Von Haehling, S., Morley, J.E., Anker, S.D., An overview of sarcopenia: Facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 1 (2010), 129–133.
8. 8 Berger, M.J., Doherty, T.J., Sarcopenia: Prevalence, mechanisms, and functional consequences. Interdiscip Top Gerontol 37 (2010), 94–114.
9. 9 Mitchell, W.K., Williams, J., Atherton, P., et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength: A quantitative review. Front Physiol, 11, 2012, 260.
10. 10 Volpato, S., Bianchi, L., Cherubini, A., et al. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: Application of the EWGSOP definition and diagnostic algorithm. J Gerontol A Biol Sci Med Sci 69 (2014), 438–446.
11. 11 Visser, M., Goodpaster, B.H., Kritchevsky, S.B., et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 60 (2005), 324–333.
12. 12 Kalyani, R.R., Corriere, M., Ferrucci, L., Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2 (2014), 819–829.
13. 13 Park, S.W., Goodpaster, B.H., Strotmeyer, E.S., et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: The Health, Aging, and Body Composition Study. Diabetes Care 30 (2007), 1507–1512.
14. 14 Park, S.W., Goodpaster, B.H., Lee, J.S., et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Health, Aging, and Body Composition Study. Diabetes Care 32 (2009), 1993–1997.
15. 15 Leenders, M., Verdijk, L.B., van derHoeven, L., et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc 14 (2013), 585–592.
16. 16 Kim, K.S., Park, K.S., Kim, M.J., et al. Type 2 diabetes is associated with low muscle mass in older adults. Geriatr Gerontol Int 14 (2014), 115–121.
17. 17 Nair, K. Sreekumaran, Aging muscle. Am J Clin Nutr 81 (2005), 953–963.
18. 18 Bianchi, L., Ferrucci, L., Cherubini, A., et al. The predictive value of the EWGSOP definition of sarcopenia: Results from the InCHIANTI Study. J Gerontol A Biol Sci Med Sci 71 (2016), 259–264.
19. 19 Kalyani, R.R., Saudek, C.D., Brancati, F.L., et al. Association of diabetes, comorbidities, and A1C with functional disability in older adults: Results from the National Health and Nutrition Examination Survey (NHANES), 1999–2006. Diabetes Care 33 (2010), 1055–1060.
20. 20 Lee, C.G., Boyko, E.J., Barrett-Connor, E., et al. Osteoporotic Fractures in Men (MrOS) Study Research Group. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 34 (2011), 2381–2386.
21. 21 Wang, C.P., Hazuda, H.P., Better glycemic control is associated with maintenance of lower-extremity function over time in Mexican American and European American older adults with diabetes. Diabetes Care 34 (2011), 268–273.
22. 22 Cetrone, M., Mele, A., Tricarico, D., Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. [review] Curr Diabetes Rev 10 (2014), 231–237.
23. 23 Giannocco, G., Oliveira, K.C., Crajoinas, R.O., et al. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol 698 (2013), 74–86.
24. 24 Drucker, D.J., Nauck, M.A., The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006), 1696–1705.
25. 25 Campbell, R.K., Rationale for dipeptidyl peptidase 4 inhibitors: A new class of oral agents for the treatment of type 2 diabetes mellitus. Ann Pharmacother 41 (2007), 51–60.
26. 26 McIntosh, C.H., Demuth, H.U., Kim, S.J., et al. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int J Biochem Cell Biol 38 (2006), 860–872.
27. 27 Penfornis, A., Bourdel-Marchasson, I., Quere, S., et al. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study. Diabetes Metab 38 (2012), 550–557.
28. 28 Monami, M., Iacomelli, I., Marchionni, N., et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20 (2010), 224–235.
29. 29 Paolisso, G., Monami, M., Marfella, R., et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?. Adv Ther 29 (2012), 218–233.
30. 30 American Diabetes Association. Standards of Medical Care in Diabetes—2015. Diabetes Care 2015;38.
31. 31 American Diabetes Association. Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39.
32. 32 Ware, J., Kosinski, M., Keller, S.D., A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 34 (1996), 220–233.
33. 33 Lee, P.G., McEwen, L.N., Waitzfelder, B., et al. Is the physical functioning of older adults with diabetes associated with the processes and outcomes of care? Evidence from Translating Research Into Action for Diabetes (TRIAD). Diabet Med 29 (2012), e321–e325.
34. 34 Ling, C.H., de Craen, A.J., Slagboom, P.E., et al. Accuracy of direct segmental multi-frequency bioimpedance analysis in the assessment of total body and segmental body composition in middle-aged adult population. Clin Nutr 30 (2011), 610–615.
35. 35 Janssen, I., Heymsfield, S.B., Baumgartner, R.N., et al. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985) 89 (2000), 465–471.
36. 36 Chien, M.Y., Huang, T.Y., Wu, Y.T., Prevalence of sarcopenia estimated using a bioelectrical impedance analysis prediction equation in community-dwelling elderly people in Taiwan. J Am Geriatr Soc 56 (2008), 1710–1715.
37. 37 Lauretani, F., Russo, C.R., Bandinelli, S., et al. Age-associated changes in skeletal muscles and their effect on mobility: An operational diagnosis of sarcopenia. J Appl Physiol (1985) 95 (2003), 1851–1860.
38. 38 Rizzo, M.R., Barbieri, M., Marfella, R., et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35 (2012), 2076–2082.
39. 39 Barbieri, M., Rizzo, M.R., Marfella, R., et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227 (2013), 349–354.
40. 40 Reijnierse, E.M., Trappenburg, M.C., Leter, M.J., et al. The impact of different diagnostic criteria on the prevalence of sarcopenia in healthy elderly participants and geriatric outpatients. Gerontology 61 (2015), 491–496.